BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25713293)

  • 1. Patterns of use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers among patients with acute myocardial infarction in China from 2001 to 2011: China PEACE-Retrospective AMI Study.
    Liu J; Masoudi FA; Spertus JA; Wang Q; Murugiah K; Spatz ES; Li J; Li X; Ross JS; Krumholz HM; Jiang L;
    J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25713293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
    Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
    Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
    Lim S; Choo EH; Choi IJ; Ihm SH; Kim HY; Ahn Y; Chang K; Jeong MH; Seung KB
    J Korean Med Sci; 2019 Nov; 34(45):e289. PubMed ID: 31760711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction.
    Lee JH; Bae MH; Yang DH; Park HS; Cho Y; Lee WK; Jeong MH; Kim YJ; Cho MC; Kim CJ; Chae SC;
    Korean J Intern Med; 2016 Mar; 31(2):267-76. PubMed ID: 26701233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
    J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
    Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin inhibition after myocardial infarction: does drug class matter?
    Winkelmayer WC; Fischer MA; Schneeweiss S; Levin R; Avorn J
    J Gen Intern Med; 2006 Dec; 21(12):1242-7. PubMed ID: 17105523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct survival benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers in revascularized coronary artery disease patients according to history of myocardial infarction.
    Nishino T; Furukawa Y; Kaji S; Ehara N; Shiomi H; Kim K; Kitai T; Kinoshita M; Morimoto T; Sakata R; Kimura T;
    Circ J; 2013; 77(5):1242-52. PubMed ID: 23291989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker.
    Hara M; Sakata Y; Nakatani D; Suna S; Usami M; Matsumoto S; Sugitani T; Nishino M; Sato H; Kitamura T; Nanto S; Hamasaki T; Hori M; Komuro I;
    Am J Cardiol; 2014 Jul; 114(1):1-8. PubMed ID: 24819900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.
    Arnold SV; Spertus JA; Masoudi FA; Daugherty SL; Maddox TM; Li Y; Dodson JA; Chan PS
    J Am Coll Cardiol; 2013 Nov; 62(19):1791-801. PubMed ID: 23973701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
    Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
    J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction.
    Ozaki Y; Imanishi T; Tanimoto T; Kashiwagi M; Tsujioka H; Sougawa H; Orii M; Shiono Y; Shimamura K; Ishibashi K; Komukai K; Ino Y; Kitabata H; Akasaka T
    Circ J; 2012; 76(6):1461-8. PubMed ID: 22453004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
    Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
    J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/β-blocks in Chinese patients before acute myocardial infarction occurs: patient characteristics and hospital follow-up.
    Gong X; Ding X; Chen H; Li H
    J Transl Med; 2018 Dec; 16(1):346. PubMed ID: 30526628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
    Shih CJ; Chu H; Ou SM; Chen YT
    Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study.
    Zullo AR; Riester MR; Erqou S; Wu WC; Rudolph JL; Steinman MA
    Drugs Aging; 2020 Oct; 37(10):755-766. PubMed ID: 32808250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
    Hess G; Preblick R; Hill J; Plauschinat CA; Yaskin J
    Congest Heart Fail; 2009; 15(4):170-5. PubMed ID: 19627290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of angiotensin converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats.
    Zhang RY; Wang LF; Zhang L; Meng XN; Li SJ; Wang WR
    Chin Med J (Engl); 2006 Apr; 119(8):649-55. PubMed ID: 16635409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.